Prostate-specific membrane antigen (PSMA) is expressed by prostate cancer cells as well as endothelial cells within the neovasculature of a number of malignancies including renal cell carcinoma (RCC). PET radiotracers that target PSMA have shown great promise for imaging RCC. Agents that target PSMA also have the potential to be used as therapeutics in patients with this malignancy.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Chang, S. S. et al. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res. 59, 3192–3198 (1999).
Rowe, S. P. et al. PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges. Prostate Cancer Prostatic Dis. 19, 223–230 (2016).
Kratochwil, C. et al. PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with 177Lu-Labeled PSMA-617. J. Nucl. Med. 57, 1170–1176 (2016).
Baum, R. P. et al. 177Lu-labeled prostate-specific membrane antigen radioligand therapy of metastatic castration-resistant prostate cancer: safety and efficacy. J. Nucl. Med. 57, 1006–1013 (2016).
Baccala, A. et al. Expression of prostate-specific membrane antigen in tumor-associated neovasculature of renal neoplasms. Urology 70, 385–390 (2007).
Rowe, S. P. et al. Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted 18F-DCFPyL PET/CT. Ann. Nucl. Med. 29, 877–882 (2015).
Sawicki, L. M. et al. Diagnostic potential of PET/CT using a 68Ga-labelled prostate-specific membrane antigen ligand in whole-body staging of renal cell carcinoma: initial experience. Eur. J. Nucl. Med. Mol. Imaging 44, 102–107 (2017).
Rhee, H. et al. Pilot study: use of gallium-68 PSMA PET for detection of metastatic lesions in patients with renal tumour. EJNMMI Res. 6, 76 (2016).
Spatz, S. et al. Comprehensive evaluation of prostate-specific membrane antigen expression in the vasculature of renal tumors: implications for imaging studies and prognostic role. J Urol. http://dx.doi.org/10.1016/j.juro.2017.08.079 (2017).
Sánchez-Gastaldo, A. et al. Systemic treatment of renal cell cancer: a comprehensive review. Cancer Treat. Rev. 60, 77–89 (2017).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
M.A.G. has served as a consultant to Progenics Pharmaceuticals, the licensee of 18F-DCFPyL. Both authors have received research funding from Progenics Pharmaceuticals.
Related links
FURTHER INFORMATION
PowerPoint slides
Rights and permissions
About this article
Cite this article
Gorin, M., Rowe, S. PSMA: a potential therapeutic target in RCC. Nat Rev Urol 14, 646–647 (2017). https://doi.org/10.1038/nrurol.2017.164
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2017.164
This article is cited by
-
Inconsistent Detection of Sites of Metastatic Non-Clear Cell Renal Cell Carcinoma with PSMA-Targeted [18F]DCFPyL PET/CT
Molecular Imaging and Biology (2019)
-
Renal Cell Carcinoma: the Oncologist Asks, Can PSMA PET/CT Answer?
Current Urology Reports (2019)
-
Recent developments of prostate-specific membrane antigen (PSMA)-specific radiopharmaceuticals for precise imaging and therapy of prostate cancer: an overview
Clinical and Translational Imaging (2019)